DOCSLIB.ORG

RS PDF Biotech Data

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
RS PDF Biotech Data RS Components: https://uk.rs-online.com/web/ Source: https://www.crunchbase.com/ Data was pulled on the 14/10/2019 from Crunchbase. A total of 2,345 acquired companies including the category 'Biotechnology' were analysed. CB Rank Announced Date Announced Announced Date Price Price Currency Founded Date Organization Name Organization Name URL Categories Headquarters Location Description (Company) Acquired by Acquired by URL full Year Precision Price Currency (in USD) Founded Date Precision Allergan https://www.crunchbase.com/organization/allerganBiotechnology, Education,Madison, Wisconsin, Medical, Pharmaceutical, UnitedAllergan States is Universities a global27,618 pharmaceuticalAbbVie company. https://www.crunchbase.com/organization/abbvie25/06/2019 2019 day 63000000000 USD 63000000000 01/01/1948 year Vitaldent https://www.crunchbase.com/organization/vitaldentBiotechnology, Dental,Madrid, Wellness Madrid, Spain Vitaldent is specializing24,424 in comprehensiveAdvent International dental services forhttps://www.crunchbase.com/organization/advent-international teeth cleaning, decay, dentistry07/06/2019 and more. 2019 day 01/01/1989 year BioDuro https://www.crunchbase.com/organization/bioduroBiotechnology, HealthSan Diego, Care, California, Pharmaceutical UnitedBioDuro States is a US-based,92,295 fully-integrated,Advent end-to-endInternational global lifehttps://www.crunchbase.com/organization/advent-international science outsourcing services27/01/2019 company with a team 2019of overday 630 in Beijing, 01/01/2005 year BioTek Instruments https://www.crunchbase.com/organization/biotek-instrumentsBiotechnology, BusinessWinooski, Development, Vermont, United LifeBioTek StatesScience, Instruments Manufacturing,100,540 focuses Wellness in theAgilent manufacturing, Technologies development,https://www.crunchbase.com/organization/agilent and sale of life science instrumentation11/07/2019 and software.2019 day 1165000000 USD 1165000000 01/01/1968 year Helio Vision https://www.crunchbase.com/organization/helio-visionBiotechnology, ClinicalLexington, Trials, Massachusetts, Travel HelioUnited Vision States develops49,961 a therapy forAldeyra rare, fibroproliferativeTherapeutics disordershttps://www.crunchbase.com/organization/aldeyra-therapeutics that lead to abnormal29/01/2019 scarring and blindness2019 after dayretina surgery. 25000000 USD 25000000 01/01/2016 year Nuevolution https://www.crunchbase.com/organization/nuevolutionBiotechnology, HealthCopenhagen, Care, Medical Hovedstaden,Nuevolution, Denmark a small22,944 molecule leadAmgen discovery company, conductshttps://www.crunchbase.com/organization/amgen-2 drug discovery in partner-funded22/05/2019 programs and2019 collaborativeday projects. 01/01/2001 year Aegerion Pharmaceuticals https://www.crunchbase.com/organization/aegerion-pharmaceuticalsBiotechnology, HealthCambridge, Care, Massachusetts, Therapeutics Aegerion United States Pharmaceuticals16,888 engagesAmryt in the Pharma development of therapeuticshttps://www.crunchbase.com/organization/amryt-pharma and pharmaceuticals20/03/2019 to treat cardiovascular2019 andday metabolic diseases. 01/01/2005 year Eximo Medical https://www.crunchbase.com/organization/eximo-medicalBiotechnology, HealthRehovot, Care, HaMerkaz, Medical IsraelDeviceEximo Medical offers8,446 a novel hybridAngioDynamics catheter technology forhttps://www.crunchbase.com/organization/angiodynamics tissue resection invascular and03/10/2019 gastrointestinal endoluminal2019 day applications. 46000000 USD 46000000 01/01/2012 year OmniComm Systems https://www.crunchbase.com/organization/omnicomm-systemsBiotechnology, InformationFort Lauderdale, Technology Florida, UnitedOmniComm States is a 91,930global provider ofAnju Electronic Software Data Capture https://www.crunchbase.com/organization/anju-softwareand eClinical technologies for16/07/2019 Clinical Trial Organizations.2019 day 01/01/1996 year Kanyos Bio https://www.crunchbase.com/organization/kanyos-bioBiotechnology, HealthCambridge, Care, Massachusetts, Life Science Kanyos United Bio States was founded11,070 with theAnokion goal of developing antigen-specifichttps://www.crunchbase.com/organization/anokion-sa immune tolerance 11/09/2019technology for two specific2019 autoimmuneday indications. 01/01/2015 year Akron Biotechnology https://www.crunchbase.com/organization/akron-biotechnologyBiotechnology Boca Raton, Florida, UnitedAkron States Biotechnology92,504 is an innovativeArcline biotechnology Investment Managementcompanyhttps://www.crunchbase.com/organization/arcline-investment-management focused on manufacturing11/09/2019 high quality products for2019 advancedday therapies. 01/01/2006 year Caprion https://www.crunchbase.com/organization/caprionBiotechnology, HealthMontréal, Care Quebec, CanadaCaprion’s highly111,169 trained, multi-disciplinaryArsenal Capital team Partners has developedhttps://www.crunchbase.com/organization/arsenal-capital-partners a highly integrated, industrialized31/07/2019 approach to 2019proteomics.day 01/01/2002 year Provista Diagnostics https://www.crunchbase.com/organization/provista-diagnosticsBiotechnology, HealthNew York, Care, New Health York, Diagnostics UnitedProvista States Diagnostics22,834 develops andAscenda commercializes BioSciences blood-basedhttps://www.crunchbase.com/organization/ascenda-biosciences diagnostic tests for the detection18/06/2019 of oncology-related2019 diseases.day 01/01/2007 year RoverMed BioSciences https://www.crunchbase.com/organization/rovermed-biosciencesBiotechnology, HealthSaint Cloud, Care, Minnesota,Life Science, United MedicalRoverMed States has developed18,092 precisionAsklepios targeted BioPharmaceutical nanocapsule technologyhttps://www.crunchbase.com/organization/asklepios-biopharmaceutical aimed at delivering17/09/2019 life saving drugs to the 2019most challengingday disease sites 01/01/2017 day Synpromics Ltd https://www.crunchbase.com/organization/synpromics-ltdBiotechnology, Genetics,Edinburgh, Medical, Edinburgh, Therapeutics City Synpromicsof, United Kingdom develops25,934 and commercializesAsklepios synthetic BioPharmaceutical promotershttps://www.crunchbase.com/organization/asklepios-biopharmaceutical to control gene expressions13/08/2019 and regulations. 2019 day 01/01/2010 year Aspen Surgical https://www.crunchbase.com/organization/aspen-surgicalBiotechnology Caledonia, Michigan, UnitedAspen States Surgical providing144,153 tools toAudax avoid surgeonsPrivate Equity leaving supplieshttps://www.crunchbase.com/organization/audax-private-equity in patients. 10/07/2019 2019 day 01/01/2004 year Innovus Pharma https://www.crunchbase.com/organization/innovus-pharmaceuticalsBiotechnology, HealthLa Jolla, Care, California, Pharmaceutical United StatesINNOVUS PHARMACEUTICALS21,545 developsAytu BioScience healthcare productshttps://www.crunchbase.com/organization/aytu-bioscience for dermatology, autoimmune,12/09/2019 respiratory and sexual2019 dysfunctionday diseases. 01/01/2011 year Isobionics https://www.crunchbase.com/organization/isobionicsBiotechnology, ChemicalGeleen, Limburg, The NetherlandsIsobionics that uses90,792 a proprietaryBASF biotechnology process forhttps://www.crunchbase.com/organization/basf the production of flavor and27/09/2019 fragrance ingredients. 2019 day 01/01/2008 year Cheetah Medical https://www.crunchbase.com/organization/cheetah-medicalBiotechnology, DeveloperNewton Center, Platform, Massachusetts, MedicalCheetah United Medical States2,795 is a device companyBaxter developing International non-invasivehttps://www.crunchbase.com/organization/baxter-international cardiac output and hemodynamic10/09/2019 monitoring devices.2019 day 230000000 USD 230000000 01/01/2001 year BlueRock Therapeutics https://www.crunchbase.com/organization/bluerock-therapeuticsBiopharma, Biotechnology,Toronto, Ontario, Health Canada Care It is a regenerative3,104 medicine company.Bayer https://www.crunchbase.com/organization/bayer-ag-germany08/08/2019 2019 day 1000000000 USD 1000000000 01/01/2016 year Labcyte https://www.crunchbase.com/organization/labcyteAlternative Medicine,San Jose, Biotechnology, California, United Life Science,Lab­cyte States Pharmaceutical Inc. is13,049 the maker of Echo®Beckman Acoustic Coulter Liquid Life SciencesHandlinghttps://www.crunchbase.com/organization/beckman-coulter-life-sciences systems for life sciences.30/01/2019 2019 day 01/01/2000 year Critical Signal Technologies https://www.crunchbase.com/organization/critical-signal-technologiesBiotechnology, HealthNovi, Michigan, Care, Security United StatesFounded in 200685,025 by security and Bestmedical Buy monitoring experthttps://www.crunchbase.com/organization/bestbuy Jeffery S. Prough, Critical Signal24/05/2019 Technologies is dedicated2019 today helping our 01/01/2006 year B-MoGen Biotechnologies https://www.crunchbase.com/organization/b-mogen-biotechnologiesBiotechnology, Genetics,Saint Paul, Health Minnesota, Care, MedicalUnitedB-MoGen States Device Biotechnologies42,052 is a genomeBio-Techne engineering startuphttps://www.crunchbase.com/organization/techne-corporation out of Minneapolis, MN. 04/06/2019 2019 day 01/01/2015 year Oncimmune https://www.crunchbase.com/organization/oncimmuneBiotechnology, Commercial,Nottingham, ManufacturingNottingham, UnitedOncimmune Kingdom engaged15,516 in developingBiodesix and commercializing itshttps://www.crunchbase.com/organization/biodesix EarlyCDT platform technology.28/06/2019 2019 day 01/01/2006 year Nightstar Therapeutics https://www.crunchbase.com/organization/nightstarxBiotechnology, Genetics,London,
Load more

Recommended publications
  • Fully Human Domain Antibody Therapeutics: the Best of Both Worlds
    Drug Discovery Fully Human Domain Antibody Therapeutics: The Best of Both Worlds By combining the therapeutic benefits of small molecule drugs with those of fully human antibodies, Domain Antibodies are expected to have strong therapeutic and commercial potential. By Robert Connelly at Domantis Robert Connelly is Chief Executive Officer of Domantis. He has over 22 years’ commercial experience of the life science sector, including that gained in the fields of diagnostics, drug discovery technologies and antibody therapeutics. Prior to joining Domantis, he was CEO of Veritas Pharmaceuticals (Los Angeles, USA), an in vivo imaging start-up company. He spent over five years with IGEN International, latterly as Senior Vice President and General Manager, Life Sciences, where he took part in the company’s IPO and financing rounds, raising $130 million. The first 11 years of his career were spent at Abbott Laboratories in sales, marketing and management positions. Domain Antibodies (dAbs) are the smallest functional variable regions of either the heavy (VH) or light (VL) binding units of antibodies. At Domantis, we are chains of human antibodies. Domantis scientists applying our proprietary know-how in dAbs to deliver have used the variable domains sequences of human human therapies that address large, unmet medical antibodies to create a series of large and highly needs in areas such as inflammation, cancer and functional libraries of fully human dAbs, with each autoimmune diseases. Three and a half years after library comprising at least 1010 different dAbs. The opening our laboratories, we have a dozen proprietary dAbs selected from these libraries are both specific therapeutic programmes underway, and an additional for their biological target and are well folded and eight therapeutic programmes with partners.
    [Show full text]
  • Power List 2018
    APRIL 2018 # 40 Editorial Upfront In My View Sitting Down With Stop and look at how far Preparing for the EU’s new What can algae teach us Sophie Kornowski-Bonnet, the industry has come data protection regulation about medicine design? Roche Partnering 09 10 – 11 20 – 21 50 – 51 100 Power List 2018 www.themedicinemaker.com Continuous Growth Fibra-Cel® disks—3-D growth matrix for perfusion and continuous processes Suspend your disbelief: > Less susceptible to shear forces, The three-dimensional Fibra-Cel matrix clogging, and fouling entraps anchorage dependent and > Ideal for secreted product and vaccine suspension cells—for optimized growth production conditions and increased yields. > Suitable for GMP production > For use in autoclavable, sterilize-in- place or BioBLU® Single-Use Vessels www.eppendorf.com/Fibra-Cel Fibra-Cel® is a registered trademark owned by Imerys Minerals California, Inc., USA and licensed to Eppendorf, Inc., USA. Eppendorf®, the Eppendorf Brand Design and BioBLU® are registered trademarks of Eppendorf AG, Germany. All rights reserved, including graphics and images. Copyright © 2018 by Eppendorf AG. tmm_epp_ad_210x266_2018_04.indd 1 28.03.18 13:34 Online this Month The Power List The 2018 Power List, starting on page 24 of this issue, features 100 of the most inspirational professionals involved in A Scientist Walks into a Bar... format to the public”. Generally, drug development. The list was compiled it involves scientists speaking on a based on reader nominations and And gives a presentation as part variety of topics, from medicine, to feedback from a judging panel – but any of Pint of Science, a global science neuroscience, to robotics and more, in list will always be subjective.
    [Show full text]
  • Kopi Af Aktivlisten 2021-06-30 Ny.Xlsm
    Velliv noterede aktier i alt pr. 30-06-2021 ISIN Udstedelsesland Navn Markedsværdi (i DKK) US0378331005 US APPLE INC 1.677.392.695 US5949181045 US MICROSOFT CORP 1.463.792.732 US0231351067 US AMAZON.COM INC 1.383.643.996 DK0060534915 DK NOVO NORDISK A/S-B 1.195.448.146 US30303M1027 US FACEBOOK INC-CLASS A 1.169.094.867 US02079K3059 US ALPHABET INC-CL A 867.740.769 DK0010274414 DK DANSKE BANK A/S 761.684.457 DK0060079531 DK DSV PANALPINA A/S 629.313.827 US02079K1079 US ALPHABET INC-CL C 589.305.120 US90138F1021 US TWILIO INC - A 514.807.852 US57636Q1040 US MASTERCARD INC - A 490.766.560 US4781601046 US JOHNSON & JOHNSON 478.682.981 US70450Y1038 US PAYPAL HOLDINGS INC 471.592.728 DK0061539921 DK VESTAS WIND SYSTEMS A/S 441.187.698 US79466L3024 US SALESFORCE.COM INC 439.114.061 US01609W1027 US ALIBABA GROUP HOLDING-SP ADR 432.325.255 US8835561023 US THERMO FISHER SCIENTIFIC INC 430.036.612 US22788C1053 US CROWDSTRIKE HOLDINGS INC - A 400.408.622 KYG875721634 HK TENCENT HOLDINGS LTD 397.054.685 KR7005930003 KR SAMSUNG ELECTRONICS CO LTD 389.413.700 DK0060094928 DK ORSTED A/S 378.578.374 ES0109067019 ES AMADEUS IT GROUP SA 375.824.429 US46625H1005 US JPMORGAN CHASE & CO 375.282.618 US67066G1040 US NVIDIA CORP 357.034.119 US17275R1023 US CISCO SYSTEMS INC 348.160.692 DK0010244508 DK AP MOLLER-MAERSK A/S-B 339.783.859 US20030N1019 US COMCAST CORP-CLASS A 337.806.502 NL0010273215 NL ASML HOLDING NV 334.040.559 CH0012032048 CH ROCHE HOLDING AG-GENUSSCHEIN 325.008.200 KYG970081173 HK WUXI BIOLOGICS CAYMAN INC 321.300.236 US4370761029 US HOME DEPOT INC 317.083.124 US58933Y1055 US MERCK & CO.
    [Show full text]
  • United States Securities and Exchange Commission Form
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 5, 2020 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 2000 Galloping Hill Road, Kenilworth, NJ 07033 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code (908) 740-4000 Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
    [Show full text]
  • BIO-2005-MK-ONLINE (Page 1)
    THE SCIENCE. THE BUSINESS. THE WORLD OF BIOPHARMACEUTICALS. 2005 MEDIA PLANNER www.biopharminternational.com THE PRINT-BASED MARKETING Display Advertising BIOPHARM The foundation of any b-to-b marketing program, print advertising allows you to BRAND touch 29,200 BPA-qualified subscribers* with your brand or product message. BioPharm International’s Build your marketing plan around the message portfolio of products allows conveyed in your print ad and utilize other channels you to reach our highly to further reinforce your message. desirable audience through multiple marketing channels. Custom Publishing Work with us to write and design a custom white paper or article Studies show integrated published as an advertorial in the pages of BioPharm. marketing is the key to successfully delivering your Insert A unique way to deliver white papers, brochures or any other collateral message to today’s buyer. material to our readers. Reinforce your message to the most important audience Polybag in your market—ask your Talk about premium placement! Send your printed piece as a ride-along advertising sales manager and readers will get the message as soon as the issue hits their desk. to design an integrated program Direct Mail utilizing the channels that best Planning a direct mail campaign to reinforce your ad message? meet your marketing objectives. Rent our list to ensure your marketing material reaches your most important audience. Post-It Note A truly unique way to send your message to our readers, Post-It Notes serve as front cover reminders about your brand. Use Post-Its to call out your ads in the issue or run 6 or 12 Post-It Notes for a truly unique campaign.
    [Show full text]
  • Faculty Disclosure
    Faculty Disclosure In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity. Nature of Relevant Financial Relationship Last Name Commercial Interest What Was Received For What Role AbbVie, Allergan/ Tobira Therapeutics Inc, Gilead Research Grant Research Balart Sciences Inc, Pfizer, Salix Pharmaceuticals AbbVie, Merck Honorarium Advisory Board Bau None N/A N/A Benz None N/A N/A AbbVie, Arbutus Biopharma, Dieterich Gilead Sciences, Inc., Bristol- Research Grant Consultant Myers Squibb, Merck Bayer HealthCare Pharmaceuticals, Gilead Sciences Honorarium Speaking, Consultant Inc. Bristol-Myers Squibb, Gilead Speaking, Advisory Sciences, Inc, Salix Honorarium Frenette Board Pharmaceuticals, Inc, Merck Intercept Pharmaceuticals Honorarium Advisor Conatus Pharmaceuticals Inc Honorarium Consulting Principle Investigator, Research Grant, Han Gilead Sciences,
    [Show full text]
  • Breaking Eroom's
    Breaking Eroom’s Law Michael S. Ringel, Jack W. Scannell, Mathias Baedeker and Ulrik Schulze https://doi.org/10.1038/d41573-020-00059-3 Supplementary Box 1 | Data and analysis Breaking Eroom’s Law The count and value of NMEs relative to R&D spend comes from BCG’s New Therapeutic Drug (NTD) Database, which is also the source of BCG’s annual publication in Nat. Rev. Drug. Discov. showing trends in count and value over time.1 FDA approvals are from FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER),2 peak sales estimates are from EvaluatePharma®,3 and R&D spend data are from BCG Value Science, inflation-adjusted using the standard global GDP-based inflator from the Economist Intelligence Unit.4 For additional details on methodology, see Schulze, Baedeker, Chen and Greber.5 Eroom’s Law is linear on a log scale through 2010, with an average increase approximately 12% per annum, or a halving of productivity approximately every seven years. If this holds true even after 2010, we would see a continuation of the linear development of the number of drugs approved per billion US$ R&D spending when using a logarithmic scale. To demonstrate that the deviation from regression after 2010 is statistically relevant we assumed the following: 1) Eroom's law is true up to 2010. 2) Eroom's law is not true between 2010 and 2018. To confirm our assumptions, we used a log-linear regression to describe the number of new molecular entities (NMEs) approved by the US FDA per billion US$ R&D spending from 1950–2010.
    [Show full text]
  • Manufacturers and Wholesalers Street
    Nevada AB128 Code of Conduct Compliant Companies Manufacturers and Wholesalers Street City ST Zip 10 Edison Street LLC 13 Edison Street LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Electrophysiology (including Kalila Medical 2- 2016)) Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. APGA-2 Abbott Park IL 60064 Abbott Medical Optics Abbott Molecular Division Abbott Nutrition Products Division Abbott Vascular Division (includes Tendyne 9-2015) AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 Acadia Phamaceuticals 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 Accelero Health Partners, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Accuri Cyometers, Inc. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10532 AcriVet, Inc. Actavis W.C. Holding, Inc. Morris Corporate Center III, 400 Interpace Parkway Parsippany NJ 07054 Actavis , Inc. Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Activis 400 Interpace parkway Parsippany NJ 07054 A-Dec, Inc. 2601 Crestview Dr. Newberg OR 97132 Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Advanced Vision Research, Inc., dba Akorn Consumer Health Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142 Aesculap Implant Systems, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesthera Corporation Afaxys, Inc. PO Box 20158 Charleston SC 29413 AGMS, Inc. Akorn (New Jersey) Inc. Page 1 of 23 Pages 2/15/2017 Nevada AB128 Code of Conduct Compliant Companies Akorn AG (formerly Excelvision AG) Akorn Animal Health, Inc.
    [Show full text]
  • Drug Delivery Technology Y
    * DDT Nov-Dec 2007 Working 11/9/07 2:29 PM Page 1 November/December 2007 Vol 7 No 10 IN THIS ISSUE Company Profiles 12 Drug Delivery Technologies 58 Excipients, Polymers, Liposomes & Lipids 78 Contract Pharmaceutical & Biological Development Services 83 Machinery & Laboratory Equipment and Software 96 Technology Showcase 102 The science & business of specialty pharma, biotechnology, and drug delivery www.drugdeliverytech.com * DDT Nov-Dec 2007 Working 11/9/07 2:39 PM Page 2 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 3 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 4 November/December 2007 Vol 7 No 10 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Coming in 2008 Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Drug Delivery Weekly & Fax: (703) 548-3733 E-mail: [email protected] Specialty Pharma News E-mail: [email protected] West Coast Warren De Graff Western Regional Manager 818 5th Avenue, Suite 301 San Rafael, CA 94901 Tel: (415) 721-0644 Fax: (415) 721-0665 E-mail: [email protected] 0 The weekly electronic newsletter from the publishers of Drug 1 International o N Delivery Technology and Specialty Pharma will provide over 12,000 Ralph Vitaro 7 219 Changebridge Road l o subscribers with the latest news of business deals, alliances, and V Montville, NJ 07045 Tel: (973) 299-1200 7 technology breakthroughs from the pharmaceutical, specialty 0 Fax: (973) 299-7937 0 2 pharmaceutical, drug delivery, and biotechnology industries.
    [Show full text]
  • EP Vantage Interview - Silence Hoping to Have Something to Shout About in 2009
    December 22, 2008 EP Vantage Interview - Silence hoping to have something to shout about in 2009 Lisa Urquhart With its first product expected to go into the clinic potentially as early as January, Silence Therapeutics is hoping that 2009 will be year it has something to shout about and one that will reverse the alarming share price decline that has seen the company’s valuation slip from a high of over £170m in June 2007 to £21.6m today. Silence is one of a growing number of companies working in RNA interference (RNAi) and particularly short interfering RNA (siRNA), which work by selectively silencing or inactivating genes related to certain diseases. It is importantly one of only two companies that have composition of matter patent protection for their siRNA drugs. Speaking to EP Vantage, Iain Ross, chief executive of Silence, says: “It’s a big year coming up for us.” The group has spent most of the last 12 months strengthening its IP position, and next year comes the important move of the group’s lead candidate Atu027 into the clinic, an event Mr Ross says should take place in the first quarter of the year. Many expect it could be as soon as the end of January. Partnering focus What is less expected is the speed at which Mr Ross intends to partner the drug, which is being developed in solid tumours, with an emphasis on lung cancer. “We would be looking at doing something either at the end of 2009 or the beginning of 2010,” he says. Key to partnering discussions will be the drug demonstrating good safety data in a number of cancer patients, which could be the catalyst to starting talks with big pharma who have already started to ask about Atu027.
    [Show full text]
  • NASDAQ Stock Market
    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
    [Show full text]
  • List of Section 13F Securities
    List of Section 13F Securities 1st Quarter FY 2004 Copyright (c) 2004 American Bankers Association. CUSIP Numbers and descriptions are used with permission by Standard & Poors CUSIP Service Bureau, a division of The McGraw-Hill Companies, Inc. All rights reserved. No redistribution without permission from Standard & Poors CUSIP Service Bureau. Standard & Poors CUSIP Service Bureau does not guarantee the accuracy or completeness of the CUSIP Numbers and standard descriptions included herein and neither the American Bankers Association nor Standard & Poor's CUSIP Service Bureau shall be responsible for any errors, omissions or damages arising out of the use of such information. U.S. Securities and Exchange Commission OFFICIAL LIST OF SECTION 13(f) SECURITIES USER INFORMATION SHEET General This list of “Section 13(f) securities” as defined by Rule 13f-1(c) [17 CFR 240.13f-1(c)] is made available to the public pursuant to Section13 (f) (3) of the Securities Exchange Act of 1934 [15 USC 78m(f) (3)]. It is made available for use in the preparation of reports filed with the Securities and Exhange Commission pursuant to Rule 13f-1 [17 CFR 240.13f-1] under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of March 15, 2004, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending March 31, 2004. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by Section 13(f)(1) and Rule 13f-1 thereunder.
    [Show full text]